Cancer patients get continued access to promising targeted therapy
NCT ID NCT03194893
First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 26 times
Summary
This study offers ongoing treatment with alectinib or crizotinib to people with ALK- or RET-positive cancer who were already benefiting from these drugs in a previous Roche trial. The goal is to keep providing the medication safely while monitoring side effects and survival. About 200 participants are enrolled across multiple countries.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Adana Ac?badem Hospital Oncology Department
Adana, 01130, Turkey (Türkiye)
-
Azienda Ospedaliera Di Perugia Ospedale s. Maria Della Misericordia
Perugia, Umbria, 06132, Italy
-
Azienda Ospedaliera San Camillo Forlanini - Unità Operativa Complessa di Pneumologia Oncologica 1
Rome, Lazio, 00151, Italy
-
Azienda Ospedaliero-Universitaria Careggi
Florence, Tuscany, 50139, Italy
-
CHU de Toulouse - Hôpital Larrey
Toulouse, 31059, France
-
Centre Francois Baclesse
Caen, 14076, France
-
Centre Georges François Leclerc
Dijon, 21000, France
-
Centre Leon Berard
Lyon, 69008, France
-
Centre Oscar Lambret
Lille, 59020, France
-
Chao Family Comprehensive Cancer Center
Orange, California, 92868, United States
-
City Clinical Oncology Hospital
Moscow, Moscow Oblast, 143423, Russia
-
Ege University Medical Faculty
Izmir, 35040, Turkey (Türkiye)
-
FSBSI "Russian Oncological Scientific Center n.a. N.N. Blokhin"
Moscow, Moscow Oblast, 115478, Russia
-
Groupe Hospitalier Sud - Hôpital Haut Lévêque
Pessac, 33600, France
-
Hacettepe Uni Medical Faculty Hospital
S?hhiye, Ankara, 06100, Turkey (Türkiye)
-
Hopital Pontchaillou - CHU de Rennes
Rennes, 35033, France
-
Hopital Robert Schuman
Vantoux, 57070, France
-
Hospital Universitari Dexeus - Grupo Quironsalud
Barcelona, 08028, Spain
-
Hospital Universitario La Paz
Madrid, 28046, Spain
-
Hospital del Mar
Barcelona, 08003, Spain
-
Irccs Centro Di Riferimento Oncologico (CRO)
Aviano, Friuli Venezia Giulia, 33081, Italy
-
Istanbul Uni Capa Medical Faculty
Istanbul, 34093, Turkey (Türkiye)
-
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, 02114, United States
-
Queen Elizabeth Hospital Department of Clinical Oncology
Kowloon, Hong Kong
-
Queen Mary Hospital
Hong Kong, Hong Kong
-
Samsung Medical Center
Seoul, 06351, South Korea
-
Seoul National University Hospital
Seoul, 03080, South Korea
-
University ?linic of headaches
Moscow, Moscow Oblast, 121467, Russia
-
Uniwersyteckie Centrum Kliniczne
Gda?sk, 80-214, Poland
Conditions
Explore the condition pages connected to this study.